January 2016 Blog Posts (1)

Oasmia Confirms Data Suggesting Equal Efficacy for Novel Therapeutic Paclical® and US-Approved Abraxane®

By Sonia Portillo, Medical Writer

In the current oncology therapeutics market, an estimated $45 billion is brought in through cytogenic therapeutics. Of that amount, 70% is attributed to generic cytostatics, which are largely dominated by paclitaxel-based products Taxol and Abraxane® (Celgene). In fact, before going generic, Taxol brought in around 1.6 billion dollars annually, and it was used for 16 cancer indexes. Just last…

Continue

Added by Editorial Team on January 22, 2016 at 8:30pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+